Literature DB >> 27363386

PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy.

Michael A Gorin1, Steven P Rowe2, Jody E Hooper3, Max Kates4, Hans-Joerg Hammers5, Zsolt Szabo2, Martin G Pomper2, Mohamad E Allaf4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27363386      PMCID： PMC5516900          DOI： 10.1016/j.eururo.2016.06.019

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  7 in total

Review 1.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

2.  Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.

Authors:  S S Chang; V E Reuter; W D Heston; P B Gaudin
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

3.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

5.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Authors:  Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf
Journal:  Ann Nucl Med       Date:  2015-08-19       Impact factor: 2.668

Review 6.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Authors:  S P Rowe; M A Gorin; M E Allaf; K J Pienta; P T Tran; M G Pomper; A E Ross; S Y Cho
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

7.  Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.

Authors:  Lino M Sawicki; Christian Buchbender; Johannes Boos; Markus Giessing; Johannes Ermert; Christina Antke; Gerald Antoch; Hubertus Hautzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-21       Impact factor: 9.236
  7 in total
  17 in total

1.  Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.

Authors:  Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

2.  Novel Structured Reporting Systems for Theranostic Radiotracers.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Stefano Fanti; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Ken Herrmann; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

3.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

4.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 5.  Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Authors:  Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone
Journal:  Curr Urol Rep       Date:  2019-10-11       Impact factor: 3.092

Review 6.  A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.

Authors:  Denise S O'Keefe; Dean J Bacich; Steve S Huang; Warren D W Heston
Journal:  J Nucl Med       Date:  2018-04-19       Impact factor: 10.057

Review 7.  A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Authors:  Thomas Ahn; Matthew J Roberts; Aous Abduljabar; Andre Joshi; Marlon Perera; Handoo Rhee; Simon Wood; Ian Vela
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

8.  Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Authors:  Scott P Campbell; Alexander S Baras; Mark W Ball; Max Kates; Noah M Hahn; Trinity J Bivalacqua; Michael H Johnson; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Ann Nucl Med       Date:  2017-10-24       Impact factor: 2.668

Review 9.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 10.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.